NCI-2022-09319

Pragmatica - Lung A Prospective Randomized Study of Ramucirumab (LY3009806 NSC 749128) Plus Pembrolizumab (MK-3475 NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

This randomized study, called Pragmatica - Lung, is a research project where participants are randomly assigned to receive either a combination of two drugs, Ramucirumab and Pembrolizumab, or standard care. The participants have previously been treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC). The goal is to compare the effectiveness of the drug combination with the standard treatment for this type of cancer.

randomized: Patients are randomly assigned to one of two groups. It's like flipping a coin to decide who gets which treatment

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

stage IV: when the cancer has spread to other organs

NSCLC: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05633602

Clinical Trial Site: Einstein/Sinai/Columbia

To see all available clinical trials click here.